MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE Russian patent published in 2023 - IPC C07K16/10 A61K39/42 A61P31/14 

FIELD: biotechnology.

SUBSTANCE: invention relates to a monoclonal antibody or antigen-binding fragment selectively binding the RBD fragment of the Spike protein of the SARS-CoV-2 virus, a method of producing it, as well as to a combination containing it. Also a nucleic acid encoding the above antibody, as well as a vector containing it are disclosed. The invention also relates to an antigen receptor that selectively binds an RBD fragment of the SARS-CoV-2 Spike protein containing an antigen-binding region represented by the above antibody or an antigen-binding fragment thereof.

EFFECT: invention is effective for prevention and therapy of infection caused by SARS-CoV-2, as well as for assessing the presence of SARS-CoV-2 infection in mammals.

24 cl, 14 dwg, 3 tbl, 9 ex